文献速递脑血管病神经重症与神经感染

脑出血后急性期血压水平与临床结局的关系

Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage.
PubMed 文献 · Ann Neurol · 2019-01-07

基于ATACH-2试验中995例脑出血患者,按 randomization 后2至24小时平均每小时最低收缩压每10 mmHg分层分为5组,分析90天mRS 4-6、血肿扩大及7天内心肾不良事件。结果显示140-150 mmHg组mRS 4-6的OR为1.62,血肿扩大风险在140-150及≥150 mmHg组升高,但心肾事件在140-150及≥150 mmHg组降低。

要点

  • 脑出血后24小时内将收缩压维持在120-130 mmHg可能减少血肿扩大,但心肾并发症略有增加。
  • 与120-130 mmHg组相比,140-150 mmHg组90天mRS 4-6的OR为1.62(95%CI 1.02-2.58)。
  • 血肿扩大风险在140-150 mmHg组(OR 1.80)和≥150 mmHg组(OR 1.98)均高于120-130 mmHg组。

核心结论

  • 在脑出血后最初24小时内将收缩压降低并维持在120-130 mmHg,可通过抑制血肿扩大改善临床结局,但该获益在一定程度上被心肾并发症所抵消。

研究设计与样本

  • 对ATACH-2(脑出血抗高血压治疗2)试验中随机分组的符合条件患者进行二次分析,共纳入995例有可用收缩压数据的受试者。
  • 按随机化后2至24小时平均每小时最低收缩压每10 mmHg分层分为5组:<120、120-130、130-140、140-150和≥150 mmHg。

主要发现

  • 90天mRS 4-6的比例在<120、120-130、130-140、140-150和≥150 mmHg组分别为37.5%、36.0%、42.8%、38.6%和38.0%。
  • 校正性别、种族、年龄、发病至随机化时间、基线美国国立卫生研究院卒中量表评分、血肿体积和血肿位置后,140-150 mmHg组相对于120-130 mmHg组的OR为1.62(95%CI 1.02-2.58)。
  • 血肿扩大(定义为基线至24小时CT血肿体积增加≥6 ml)在5组中的发生率分别为16.9%、13.7%、21.4%、18.5%和26.4%;140-150 mmHg组(OR 1.80,95%CI 1.05-3.09)和≥150 mmHg组(OR 1.98,95%CI 1.12-3.51)的血肿扩大频率高于120-130 mmHg组。
  • 7天内心肾不良事件在5组中的发生率分别为13.6%、16.6%、11.5%、8.1%和8.2%;140-150 mmHg组(OR 0.43,95%CI 0.19-0.88)和≥150 mmHg组(OR 0.44,95%CI 0.18-0.96)的心肾事件频率低于120-130 mmHg组。

临床怎么用

  • 作者认为,在脑出血后最初24小时内将收缩压降低并维持在120-130 mmHg对临床结局的获益可被心肾并发症部分抵消。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the association between clinical outcomes and acute systolic blood pressure (SBP) levels achieved after intracerebral hemorrhage (ICH). METHODS: Eligible patients who were randomized to the ATACH-2 (Antihypertensive Treatment in Intracerebral Hemorrhage 2) trial (ClinicalTrials.gov: NCT01176565) were divided into 5 groups by 10-mmHg strata of average hourly minimum SBP (<120, 120-130, 130-140, 140-150, and ≥ 150 mmHg) during 2 to 24 hours after randomization. Outcomes included: 90-day modified Rankin Scale (mRS) 4 to 6; hematoma expansion, defined as an increase ≥6 ml from baseline to 24-hour computed tomography; and cardiorenal adverse events within 7 days. RESULTS: Of the 1,000 subjects in ATACH-2, 995 with available SBP data were included in the analyses. The proportion of mRS 4 to 6 was 37.5, 36.0, 42.8, 38.6, and 38.0%, respectively. For the "140 to 150" group relative to the "120 to 130," the odds ratio (OR), adjusting for sex, race, age, onset-to-randomization time, baseline National Institutes of Health Stroke Scale score, hematoma volume, and hematoma location, was 1.62 (95% confidence interval [CI], 1.02-2.58). Hematoma expansion was identified in 16.9, 13.7, 21.4, 18.5, and 26.4%, respectively. The 140 to 150 (OR, 1.80; 95% CI, 1.05-3.09) and "≥150" (1.98; 1.12-3.51) showed a higher frequency of expansion than the 120 to 130 group. Cardiorenal events occurred in 13.6, 16.6, 11.5, 8.1, and 8.2%, respectively. The 140 to 150 (0.43; 0.19-0.88) and ≥ 150 (0.44; 0.18-0.96) showed a lower frequency of the events than the 120 to 130. INTERPRETATION: Beneficial effects of lowering and maintaining SBP at 120 to 130 mmHg during the first 24 hours on clinical outcomes by suppressing hematoma expansion was somewhat offset by cardiorenal complications. ANN NEUROL 2019;85:105-113.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Toyoda K, Koga M, Yamamoto H, et al. Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage. Ann Neurol. 2019. PMID: 30421455. doi:10.1002/ana.25379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。